Genmab

Genmab's shares have doubled in three months following three positive Phase 3 cancer trial results in October, including petosemtamab combined with Keytruda which halved the risk of death in recurrent or metastatic head and neck cancer. The Danish biotech is using royalty income from drugs like Darzalex to fund acquisitions and keep larger commercial stakes in drugs it develops, having fully acquired petosemtamab and Rina-S and co-commercialized Epkinly with AbbVie. Management expects petosemtamab to be a multi-billion-dollar asset and is expanding commercial infrastructure to sell majority-owned medicines directly, while acknowledging higher costs and market risks. Genmab will report third-quarter earnings on Nov. 5. » Mais em cnbc.com

Genmab presented data on petosemtamab that show clinical success in head‑and‑neck tumors and underscore the quality of its own research. Stable revenues from the multiple myeloma drug Darzalex enable the company to expand independent oncology commercialization. The progress contributed to a fresh all‑time high for the stock. » Mais em finanzen.net

The phase‑3 LiGeR‑HN1 study shows that petosemtamab in combination with pembrolizumab met both primary endpoints in PD‑L1‑positive head and neck squamous cell carcinoma and reduced the risk of death by 50 percent. Genmab now plans to begin talks with global regulators and to present detailed results at a scientific conference. The news propelled the stock up about 25 percent and for now eases concerns about revenue risks following the Darzalex patent expiry. » Mais em deraktionaer.de

Petosemtamab showed response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer in Phase‑2 combination studies with standard chemotherapies. The safety profile was solid, with treatment-related discontinuation rates of 3–5% and no treatment-related deaths. The mature data support the global Phase‑3 program and underscore the commercial potential of the bispecific agent. » Mais em finanzen.net

Genmab climbs to a multi‑year high following positive study data, generating a fresh buy signal for trend followers. Analysts note that expanding the patient population for Epcoritamab could give the company blockbuster potential. License payments for Darzalex provide a financial cushion that supports clinical development from the company’s own cash flow and could enable further share-price gains. » Mais em finanzen.net